Drug Profile
Research programme: ethylenedicysteine glucosamine drug conjugates - CellPoint
Alternative Names: 187 Re ethylenedicysteine glucosamine; 187-Re-EC-G; Re-187-EC-G; Re-187-Oncardia and Platinum-Oncardia dual therapy; Re-188-OncardiaLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator CellPoint
- Developer CellPoint; University of Texas M. D. Anderson Cancer Center
- Class Drug conjugates; Organometallic compounds
- Mechanism of Action Apoptosis stimulants; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma; Cancer; Lung cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in B-cell lymphoma in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Lung-cancer in USA